SCHEMBL15575463

SCHEMBL15575463

COc1cccc(-c2nnc(Nc3nc4cc(OC)ccc4s3)o2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.70
HPGD P15428 8/20 0.70
KMT2A Q03164 7/20 0.70
SMN1; SMN2 Q16637 7/20 0.70
HSD17B10 Q99714 6/20 0.70
MEN1 O00255 6/20 0.70
TP53 P04637 5/20 0.70
NPC1 O15118 5/20 0.70
RAB9A P51151 5/20 0.70
KDM4E B2RXH2 9/20 0.59
MAPT P10636 8/20 0.59
LMNA P02545 6/20 0.59
TDP1 Q9NUW8 5/20 0.59
GAA P10253 3/20 0.59
USP2 O75604 2/20 0.59
PSMD14 O00487 1/20 0.59
PKM P14618 1/20 0.59
MMP13 P45452 1/20 0.59
ATG4B Q9Y4P1 1/20 0.59
DUSP3 P51452 6/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15574005 0.90 DUSP3 (0.70) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15575755 0.85 ALDH1A1 (0.71) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15575439 0.82 ALDH1A1 (1.00) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15575468 0.81 DUSP3 (0.80) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15575748 0.80 DUSP3 (0.72) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15575498 0.77 DUSP3 (0.71) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15573992 0.75 DUSP3 (0.74) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL30386804 0.75 GSK3B (0.66) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL28614995 0.75 GSK3B (0.66) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10
SCHEMBL15575656 0.74 ALDH1A1 (0.67) ALDH1A1HPGDKMT2ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2890379-B1 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS ICAHN SCHOOL MED MOUNT SINAI (US) 2019-04-03 EP claimed
US-20180127407-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators ICAHN SCHOOL MED MOUNT SINAI (US) 2018-05-10 US claimed
US-20150218148-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators ICAHN SCHOOL MED MOUNT SINAI (US) 2015-08-06 US claimed
EP-2890379-A2 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS Icahn School of Medicine at Mount Sinai (US) 2015-07-08 EP claimed
WO-2014036242-A2 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS MOUNT SINAI SCHOOL OF MEDICINE (US) 2014-03-06 WO claimed
EP-3524244-A1 BENZOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS Icahn School of Medicine at Mount Sinai (US) 2019-08-14 EP disclosed
EP-2890379-B1 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS ICAHN SCHOOL MED MOUNT SINAI (US) 2019-04-03 EP disclosed
EP-2890379-B1 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS ICAHN SCHOOL MED MOUNT SINAI (US) 2019-04-03 EP disclosed
US-20180127407-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators ICAHN SCHOOL MED MOUNT SINAI (US) 2018-05-10 US disclosed
US-9845320-B2 Benzothiazole or benzoxazole compounds as sumo activators ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-12-19 US disclosed
US-9845320-B2 Benzothiazole or benzoxazole compounds as sumo activators ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-12-19 US disclosed
US-9845320-B2 Benzothiazole or benzoxazole compounds as sumo activators ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-12-19 US disclosed
US-20150218148-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators ICAHN SCHOOL MED MOUNT SINAI (US) 2015-08-06 US disclosed
US-20150218148-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators ICAHN SCHOOL MED MOUNT SINAI (US) 2015-08-06 US disclosed
US-20150218148-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators ICAHN SCHOOL MED MOUNT SINAI (US) 2015-08-06 US disclosed
EP-2890379-A2 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS Icahn School of Medicine at Mount Sinai (US) 2015-07-08 EP disclosed
WO-2014036242-A2 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS MOUNT SINAI SCHOOL OF MEDICINE (US) 2014-03-06 WO disclosed
WO-2014036242-A2 BENZOTHIAZOLE OR BENZOXAZOLE COMPOUNDS AS SUMO ACTIVATORS MOUNT SINAI SCHOOL OF MEDICINE (US) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218148-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators SUMO2, UBA2, SUMO1 ALDH1A1 3054/4885HPGD 4321/4885KMT2A 1089/4885
US-20180127407-A1 Benzothiazole Or Benzoxazole Compounds As Sumo Activators SUMO2, UBA2, SUMO1 ALDH1A1 3054/4885HPGD 4321/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.